Novartis Acquires Amblyotech to Develop Digital Therapy for Amblyopia

Novartis to Acquire Gyroscope Therapeutics

December 22, 2021

Healthcare Services

Novartis entered into a definitive agreement to acquire all of the outstanding share capital of UK-based ocular gene therapy company Gyroscope Therapeutics. The deal includes an upfront payment of $800 million and potential additional milestone payments of up to $700 million, subject to customary regulatory approvals.

SightMD Acquires Sambursky Eye & Esthetics

January 21, 2025

Healthcare Services

SightMD (via Sight Growth Partners) has acquired Sambursky Eye & Esthetics, integrating the long-established ophthalmology practice into its New York network. The deal expands SightMD's clinical footprint in the Southern Tier of New York and adds experienced cataract and LASIK surgeons and related surgical capabilities to the platform.

Thoma Bravo Invests in Bluesight to Support Bluesight's Acquisition of Medacist

July 17, 2023

Healthcare Services

Thoma Bravo made a strategic growth investment in Bluesight to support Bluesight's acquisition of Medacist, combining two medication-management and drug-diversion analytics businesses into a single hospital pharmacy software platform. The combined company will expand Bluesight's medication intelligence capabilities and serve more than 2,000 hospitals across North America; committed financing was led by Monroe Capital and existing investor New Leaf Ventures remains invested. Financial terms were not disclosed.

Natus Sensory Acquires TheraB Medical

February 11, 2026

Medical Devices

Natus Sensory has acquired TheraB Medical, a medical technology company focused on neonatal jaundice treatment using wearable phototherapy. The deal expands Natus Sensory’s newborn care portfolio with SnugLit, a FDA-cleared swaddle-style phototherapy system designed to support family-centered care while delivering continuous therapy.

AbbVie Acquires Syndesi Therapeutics

March 1, 2022

Biotechnology

AbbVie has acquired Syndesi Therapeutics for up to US$1.0 billion, including US$130 million upfront, to strengthen its neuroscience portfolio and accelerate Syndesi's lead SV2A program SDI-118 into later-stage development. Syndesi was a Novo Seeds / UCB spin-out backed by Novo Holdings and a syndicate of Belgian and international investors.

Nextech Acquires TouchMD

October 11, 2022

Healthcare Services

Nextech has acquired TouchMD, a visual consultation, marketing, and imaging software platform serving plastic surgery, medspa, dermatology, and ophthalmology practices. The deal integrates TouchMD’s patient-facing touchscreen and marketing capabilities into Nextech’s EHR and practice management platform to enhance both the digital and in-person patient and clinical experience for specialty practices.